Envoy Medical reports Q2 clinical progress, cash $5.3M; CPT codes for Esteem device effective July 1

Envoy Medical, Inc.

2025-Q2 EPS reported -$0.62 revenue$124,000

All 10 Acclaim cochlear implant trial participants activated; no serious adverse events at one-month follow-up.
Five CPT codes for totally implantable active middle ear implants (Esteem) approved by AMA, effective July 1, 2025.
R&D expenses decreased to $2.485M from $2.6M; G&A increased $0.5M due to severance accrual.
Cash balance $5.3M as of June 30, 2025; net revenues increased by $10K YoY.
Subsequent to quarter end, two US and three Australian patents issued to strengthen IP portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.